Skip to main content

Mylan CEO Tries to Shift Focus

Amid numerous calls for state and federal investigations over pricing of its EpiPen, the drug company Mylan struck back, saying that 55 percent of the price goes to “middleman’’ insurers.

Republish
Lead image for this article

Amid numerous calls for state and federal investigations over pricing of its EpiPen, the drug company Mylan struck back, saying that 55 percent of the price goes to “middleman’’ insurers. (Becker’s Hospital Review)

Texans need truth. Help us report it.

Independent Texas reporting needs your support. The Texas Tribune delivers fact-based journalism for Texans, by Texans — and our community of members, the readers who donate, make our work possible. Help us bring you and millions of others in-depth news and information. Will you support our nonprofit newsroom with a donation of any amount?

Support independent Texas news

Become a member. Join today.

Choose an amount or learn more about membership.

$20 $25 $50 Other
Donate now

Information about the authors

Sarah Schroeder’s staff photo

Learn about The Texas Tribune’s policies, including our partnership with The Trust Project to increase transparency in news.

Explore related story topics